tbuckley/cabot-search huggingface dataset:
FRI0063 How is fatigue associated with comorbidity burden, disease activity, and disability in patients with rheumatoid arthritis? results from 34 countries in the quest-ra program
Authors: K. L. Grøn, L. M. Ørnbjerg, M. L. Hetland, T. Sokka-Isler
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Persistent fatigue is a major problem for many patients with RA. Knowledge is limited regarding the contribution of inflammation, functional status and comorbidity burden on the level of fatigue, and it is unknown whether such associations vary across different RA populations. <h3>Objectives</h3> To analyze in RA patients associations between fatigue score, disease activity, disability and comorbidities in rich and poor countries. <h3>Methods</h3> 9,874 patients from 34 countries (16 with high gross domestic product (GDP) (&gt;24.000 US dollars (USD) pr. capita) and 18 with low-GDP countries (&lt;24.000 USD)) participated in the Quantitative Standard monitoring of Patients with RA (QUEST-RA) study. The prevalence of 31 comorbid conditions, fatigue (0-10 cm VAS-scale), disease activity in 28 joints (DAS28), and physical disability (Health Assessment Questionnaire score (HAQ)) were assessed. Univariate and multivariate linear regression analyses were performed to assess the association between fatigue, comorbidities, disease activity, disability and GDP. <h3>Results</h3> The median fatigue score was 4.4. In low-GDP countries 25.4% of the patients had a high level of fatigue (&gt;6.6) compared with 23.0% in high-GDP countries (p&lt;0.001). In univariate analysis, fatigue increased with increase in number of comorbidities, disease activity and disability in both high- and low-GDP countries. In multivariate analysis these 3 variables explained 29.4% of the variability (table). Fatigue was overall higher in low-GDP countries, which was explained by higher disease activity. Overall, patients had a median of 2 comorbid conditions and the percentage of patients with comorbidities was higher in high-GDP countries. <h3>Conclusions</h3> Fatigue remains a widespread problem. Regardless of GDP, comorbid burden, disease activity and disability predicted approx. 30% of the variability in fatigue. <h3>Disclosure of Interest</h3> None Declared
P130 Feasibility Study Of A Primary Care Screening Tool For Occupational Asthma
Authors: G. Walters, D. Fitzmaurice, J. Ayres
Journal: Thorax (2014)

<h3>Introduction</h3> Occupational asthma (OA) accounts for 1 in 6 cases of adult-onset asthma and is associated with an estimated societal cost in the UK of £100 million/annum.<sup>1</sup> However many workers with OA go undiagnosed or experience a lengthy delay in diagnosis,<sup>2</sup> and primary healthcare professionals fail to enquire about patients’ occupations and the effect of work on asthma symptoms.<sup>3</sup> We evaluated the feasibility of introducing an electronic screening tool for OA in primary care. <h3>Methods</h3> A prospective feasibility study was undertaken over a 3-month period in 4 primary care practices in Birmingham, UK. Practices modified their existing electronic health records (one of: EMIS, SystmOne, Vision) with a customised asthma review template embedding the questions “What is your occupation?” and “Are your symptoms better away from work on days away/on holiday?” Baseline practice-level data were gathered and at the end of the study period all exposed healthcare professionals (GPs, practice nurses) were invited to complete an online questionnaire intended to evaluate utility and willingness to use the tool. <h3>Results</h3> Prevalence of Read-coded asthma was 5.6–8.2% and Read-coded OA was 0–0.7%. All 4 practices incorporated the screening tool without any technical difficulty. 24/52 (46%) exposed GPs/nurses returned questionnaires, of whom 10 (42%) had used the tool; uptake was higher (85%) in those professionals who were given brief training. Healthcare professionals who did use the screening tool found it to be user-friendly (clear, concise, logical) with no perceived procedural or IT difficulties or significant added burden. Responders were less confident (44% agreed/strongly agreed) about how to act when patients had work-related asthma symptoms and 78% agreed/strongly agreed that further training in managing health aspects of suspected occupational asthma would improve the screening tool. <h3>Conclusion</h3> An electronic screening tool for OA can be easily and quickly incorporated into existing asthma disease management systems. Its utility could be greatly improved by user instruction and training in further clinical management of the patient with work related asthma symptoms. <h3>References</h3> Ayres <i>et al</i>. <i>Thorax</i> 2011;66(2):128–33 Fishwick <i>et al</i>. <i>PRCJ</i> 2007;16:304–10 Walters <i>et al</i>. <i>Occup Med</i> 2012;62:570–3
AB0590 Differential Platelet Count in Active versus Inactive Anca-Associated Vasculitis (AAV) and Aav-Patients with Systemic Infections
Authors: P. Willeke, H. Becker, B. Schlüter, A. Jacobi
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> There is increasing evidence that platelets (PLT) are protagonists of inflammation in addition to their haemostatic role. <h3>Objectives</h3> To analyse PLT counts in patients with ANCA-associated vasculitis (AAV) at different states (active disease, in remission and during systemic infections) and to correlate the data with clinical parameters and markers of inflammation. <h3>Methods</h3> PLT counts of patients with newly diagnosed active AAV were analysed before initiation of therapy and in remission. Results were correlated to clinical manifestations of AAV, the Birmingham Vasculitis Activity Score (BVAS) and laboratory findings. In addition platelets were analysed during systemic infections in AAV patients. <h3>Results</h3> We identified 81 patients with active disease before therapy was initiated and 18 patients with AAV and evidence for systemic infections (age 58.7±16.9, 25 were female). Infections were pneumonia (n=14) and febrile urinary tract infections (n=4). PLT counts were significantly higher in patients granulomatosis with polyangiitis (n=52; 414±150 PLT/nl) compared to patients with microscopic polyangiitis (n=23; 333±109 PLT/nl) or eosinophilic granulomatosis with polyangiitis (n=12; 358±141 PLT/nl); (p&lt;0.01). PLT in all active AAV patients groups were significantly higher than in AAV-patients with systemic infection (225±77 PLT/nl; p&lt;0.01). After receiving remission PLT decreased significantly in all AAV patients groups (231±85 PLT/nl; p&lt;0.01). There was a strong correlation of PLT and the BVAS score (r=0.461; p&lt;0.001) and a weaker correlation of PLT with leukocyte counts and the CRP-value during active disease. <h3>Conclusions</h3> PLT are increased in patients with active AAV and correlate with the disease activity index. PLT counts may help to differentiate between active disease and systemic infections. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5464
Abstract 5205: Selectively high Wnt pathway activity in subpopulations of colon cancer cells and its significance for tumor initiation
Authors: David Horst, Ramesh A. Shivdasani
Journal: Cancer Research (2011)

Abstract Several cell surface markers that are reported to enrich for tumor-initiating colon cancer cells are presumed targets of the canonical Wnt/beta-catenin pathway. Furthermore, colon cancers typically express the Wnt-effector beta-catenin in a heterogeneous pattern, with strong nuclear expression detected only in a small fraction of tumor cells. We therefore hypothesized that high beta-catenin expression and Wnt pathway activity mark a tumorigenic subpopulation. To label viable tumor cells according to the level of Wnt pathway activity, we constructed lentiviral vectors that express GFP under control of an optimal, beta-catenin-responsive TCF/LEF1 promoter (TOP-GFP). We transduced primary colon cancer xenografts and two well characterized colon cancer cell lines with these vectors, used flow cytometry to isolate cell subpopulations with differential GFP expression, and examined these subpopulations for tumorigenicity and gene expression. High GFP expression accurately marked tumor cells with nuclear beta-catenin immunostaining in Caco2 but not SW1222 cells and in a fraction of primary colon cancer xenografts. Gene expression analysis in the concordant cases was consistent with increased Wnt-pathway activity within the GFP-high cell population, including high expression of the putative stem cell markers CD133, CD44 and LGR5. In SW1222 cells and some primary tumor xenografts, the GFP-high fraction correlated poorly with nuclear beta-catenin localization and GFP flow cytometry did not separate cells with a gene expression profile suggesting Wnt pathway activity. Among these various sources, only Caco2 cells showed increased tumorigenicity of GFP-high cells in immunodeficient mouse xenografts. The utility of TOP-GFP and related reporters to identify tumor-initiating colon cancer cells with high Wnt activity thus varies among primary human colorectal tumors and established cell lines. Furthermore, Wnt pathway activity might fluctuate substantially within individual tumor cells. We conclude that high Wnt activity among tumor cell subpopulations does not necessarily signify tumor-initiating potential. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5205. doi:10.1158/1538-7445.AM2011-5205
Abstract 4821: Plasma retinol, but not 25-OH vitamin D or vitamin E, is associated with increased survival in colorectal cancer patients.
Authors: Robert V. Cooney, Weiwen Chai, Adrian A. Franke, Christian Caberto, Lynne R. Wilkens, Laurence N. Kolonel, Laurie Custer, Cynthia Morrison, Loic Le Marchand
Journal: Cancer Research (2013)

Abstract OBJECTIVE: To determine the association of lipid-soluble vitamin status with survival in colorectal cancer patients. METHODS: Using stored patient plasma samples from a multiethnic population-based case-control study of colorectal cancer, we determined associations of post-treatment blood levels of retinol, 25 OH-vitamin D, and Vitamin E with survival. Patients (n = 455) were followed (mean of 8 years) after phlebotomy, during which time 20% died of colorectal cancer and 24% from other causes. Hazard ratios (HR) were estimated by Cox proportional hazards regression with adjustment for stage and age at diagnosis, ethnicity, sex, and smoking status. RESULTS: A strong inverse association with all-cause mortality was observed for plasma retinol (Ptrend &amp;lt;0.0001), with similar significant trends observed for both colorectal cancer-specific deaths and other causes of death (P for heterogeneity = 0.43). The inverse association between retinol and all cause mortality was consistently observed for both sexes, subjects of Caucasian and Japanese ancestry, and for both rectal cancer and colon cancer. Overall no significant associations were observed for plasma 25-OH vitamin D or vitamin E with survival. CONCLUSIONS: Results are consistent with a direct relationship between low vitamin A status and poor survival among colorectal cancer patients. The absence of a significant association for 25-OH vitamin D levels with survival may be related to the generally higher circulating levels of 25-OH vitamin D in residents of Hawaii where the study was conducted, and results may differ in northern climates and in darker pigmented patients. If verified through larger prospective studies, future complementary intervention trials involving the assessment of vitamin A status and supplementation of individuals with inadequate levels may be warranted. Citation Format: Robert V. Cooney, Weiwen Chai, Adrian A. Franke, Christian Caberto, Lynne R. Wilkens, Laurence N. Kolonel, Laurie Custer, Cynthia Morrison, Loic Le Marchand. Plasma retinol, but not 25-OH vitamin D or vitamin E, is associated with increased survival in colorectal cancer patients. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4821. doi:10.1158/1538-7445.AM2013-4821
THU0388 Demyelinating Lesions in BehÇEt's Diseas as A Form of Parenchymal Involvement
Authors: L. González, J.R. González, E. Santos, M. González, L. Valle, J. De la Fuente
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Neurologic involvement in Behçet9s disease ocurrs in 5-10% of cases. There are two patterns: parenchymal o non parenchymal involvement. Demyelinating lesions is a rare form of parenchymal afectation. <h3>Objectives</h3> Our objective is to describe the clinical manifestations, laboratory test, the location of demyelinating lesions, treatment and evolution of these patients. <h3>Methods</h3> A retrospective study was carried out in patients diagnosed of Behçet9s disease between January 1990 and december 2013. The diagnosis was based on International criteria for diagnosis of Behçet9s disease (International Study Group of Behçet9s Disease), Magnetic Resonance Imaging (MRI) of the brain and results of cerebrospinal fluid. <h3>Results</h3> 32 patients were diagnosed of Behçet9s disease during this period, and 6 (18.7%) of them had demyelinating lesions in MRI. Mean age at diagnosis was 31 (15- 62) years and 4 (66.6%) were women. Clinical manifestations: headache in all, alteration of cranial nerves in 4 (66.6%) -two with bilateral optic neuritis and two with recurrent peripheral facial paralysis-, sensory deficits in 3 (50%), seizures in 2 (33.3%), Lhermitte9s sign in 2 (33.3%), urinary incontinence in 3 (50%), ataxia in 1and transient motor deficit in 1. Three patients had low titer of positive ANA. The cerebrospinal fluid analysis showed no pleocytosis or elevated protein in any of them and three showed oligoclonal bands (50%). The MRI with gadolinium showed T2-weighted signal abnormality in the white matter in all of them (supratentorial and infratentorial). One patient had progression of lesions with involvement of the spinal cord and brainstem. Treatment: colchicine in 3, azathioprine in 3, oral corticosteroids in 3 and pulses of metilprednisolone in 5. In evolution, two patients are stable with low doses of corticosteroids; one remains stable without any treatment; one presents relapse despite infliximab and another progresses clinically and radiologically associated with poor adherence to treatment. One remains stable with adalimumab. <h3>Conclusions</h3> Demyelinating lesions in Behçet disease are frequent and the clinical course may clinically and radiologically mimic MS. All patients with demyelinating lesions should be required about symptoms of systemic disease and a full autoantibodies investigation should be carried out. Patients should be followed for years, since the possibility of presenting a systemic disease is high (even if the autoantibodies are negative in the first investigation). <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4671
Roger Bacon and the beginnings of experimental science in Britain
Authors: Eric Sidebottom
Journal: Journal of the Royal Society of Medicine (2013)

Roger Bacon is something of an enigma. He has been called many things – ‘Britain’s first scientist’, ‘wonderful doctor’, ‘conjurer’ and ‘magician’. Many of the details of his life are uncertain and they have been discussed and argued about by scholars for centuries. He is generally thought to have been born in Ilchester, Somerset, around 1214, although some authors have put his date of birth as late as 1220. There is good evidence that he was in Paris in 1245 and 1251, but it is uncertain if he ever actually studied in Oxford. If he did, he would have met Robert Grosseteste, often described as Oxford University’s first Chancellor (although his role is better described as ‘master of students’ (magister scholarium).

Bacon’s entry into the Franciscan order, plausibly in 1257, is also conjectural; but it is clear that his relationship with the Franciscan hierarchy was, at times, rather stormy.1 He was openly critical of some of their values and beliefs and it was not surprising that they sometimes tried to muzzle him. Again the details of his alleged ‘imprisonment’ are unclear.

It is likely that Bacon spent the last years of his life in the Franciscan House in Oxford, where he died and was buried in 1292.
INSIGHTS INTO TIMING, RISK FACTORS, AND OUTCOMES OF NEUROLOGIC EVENTS AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT IN THE PARTNER-I TRIAL
Authors: Samir R. Kapadia, Shikhar Agarwal, D. Craig Miller, John Webb, Michael Mack, Stephen Ellis, Howard Herrmann, Augusto Pichard, E. Murat Tuzcu, Lars Svensson, Craig Smith, Jeevanantham Rajeswaran, Susheel Kodali, Raj Makkar, Vinod Thourani, Eugene Blackstone, Martin Leon
Journal: Journal of the American College of Cardiology (2015)
P-236 Other RAS mutations incidence in CRCm in routine clinical practice: a center experience
Authors: B. Gonzalez Astorga, M.T. Delgado Urena, R. Lopez Castro, E. Gonzalez-Flores, A. Segura Perez, V. Conde, J. Garcia-Garcia, C. Sanchez-Toro, J.M. Jurado Garcia, A. Villaescusa, F. Galvez Montosa
Journal: Annals of Oncology (2015)
Abstract P4-11-22: The Role of Postmastectomy Radiation in Breast Cancer Patients with One to Three Positive Axillary Lymph Nodes
Authors: NA AboTouk, DH Zayed, MM Abdulla, SG. Younies
Journal: Cancer Research (2010)

Abstract Background: Adjuvant radiotherapy in T1-T2 invasive breast carcinoma and 1-3 positive lymph nodes is controversial due to discrepancies in the reported locoregional recurrence risks and survival data. Purpose: This work aims to explore the effectiveness of postoperative radiation therapy in patients with 1-3 positive axillary lymph nodes treated by modified radical mastectomy with systemic chemotherapy with or without hormonal treatment on locoregional recurrence and survival rates. Patients and methods: One hundred and thirteen breast cancer patients with T1 or T2 tumors and 1-3 positive axillary lymph nodes, treated by modified radical mastectomy were registered in Clinical Oncology and Nuclear Medicine Department of Mansoura &amp; Tanta University Hospitals in the period between January 1995 and December 1998. Of the 113 patients, 55 patients received postoperative radiotherapy while 58 patients did not receive it. Results: Postoperative radiotherapy reduced the incidence of locoregional recurrence from 18.2% to 5.2% (P=0.03). Distant metastases was 22.4% in the radiotherapy group of patients in comparison to 40% (P= 0.04). Disease free survival and overall survival were prolonged with postoperative radiotherapy received group (P= 0.03, 0.05) respectively. The risk factors including tumor size, grading and number of dissected axillary lymph nodes were of statistically significant value regarding both locoregional recurrence rates and survivals on the univariate analysis. On multivariate analysis they were statistically significant regarding disease free and overall survivals. Conclusion: Postoperative radiotherapy significantly reduces locoregional recurrence and survival in patients with 1 -3positive axillary lymph nodes. Patients with high risk factors including tumors ≥2cm, grade III and inadequate lymph node dissection are more likely to benefit from radiotherapy. Key words: breast cancer, postmastectomy radiation, Positive lymph nodes, locoregional recurrence, risk factors. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-11-22.
P5-13-22: Gene Expression Profiles Predict Pathological Complete Response to Standard Neoadjuvant Fluorouracil, Doxorubicin, and Cyclophosphamide and Paclitaxel with or without Trastuzumab in Early Breast Cancer.
Authors: K Tamura
Journal: Cancer Research (2011)

Abstract Background To examine the feasibility of gene expression signature as a predictor of pathological complete response (pCR) to sequential fluorouracil, doxorubicin, and cyclophosphamide (FEC) and weekly paclitaxel (P) with or without trastuzumab (T) neoadjuvant chemotherapy. Materials and Methods: We have conducted consecutive two prospective phase II, establishing training and validation sets, with similar eligible criteria include, stage IIA-IIIC, chemotherapy-naïve, measurable disease, age ≥ 20, PS 0/1, and adequate organ function. Patients were treated preoperatively with 4 cycles of FEC (500/100/500 mg/m2) followed by 12 cycles of weekly P (80 mg/m2) with or without T (2mg/kg). Patients underwent pretreatment fine-needle biopsy for cDNA microarray using Affimetrix Gene Chip U133 plus 2.0 arrays with 30,000 differential expressions of various genes. We ranked gene probes from training sets according to a predictive power concerning pCR by Wilcoxon, and validated them using validation sets by SVM. Results: Between July 2007 and December 2010, 122 patients were enrolled in the two consecutive prospective studies (training: 89 pts, validation: 33 pts). Median age was 51. PS 0/1: 115/7; Stage IIA/IIB/IIIA/IIIB/IIIC: 30/57/20/14/1; Histological subtype: ER+HER2− (LA) / ER+HER2+ (LB) / ER-HER2− (TN) / ER-HER2+ (enrich-HER): 51/18/24/29. All patients have received curable operations. pCR rate was 31.1% (LA; 2.0%, LB; 44.4%, TN; 37.5%, enrich-HER; 69.0%). 104 (85.2%) sufficient mRNA for cDNA microarray from individual primary breast cancer tissues fine-needle biopsy are available. As reported previously, the breast cancers were classified into a Luminal A/B, Basal-like, HER2−enriched, Claudin-low intrinsic subtypes, indicating a high quality of the representative method. In HER2 positive breast cancer, HER2−enriched subtype was a reproductive predictive marker. In contrast, In HER2 negative breast cancer, three genes (N-myc and STAT interacter, Tryptophanyl-tRNA synthetase, and IQCE) and basal-like subtype were validated as the predictors of pCR. The three genes were also identified as predictors of pCR in the triple negative population. Conclusions: Specific gene expression profiles predict pCR to standard neoadjuvant regimen, especially in triple negative breast cancer. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-13-22.
A Comparison of Glyburide and Insulin in Women with Gestational Diabetes Mellitus
Authors: Oded Langer, Deborah L. Conway, Michael D. Berkus, Elly M.-J. Xenakis, Olga Gonzales
Journal: New England Journal of Medicine (2000)

Women with gestational diabetes mellitus are rarely treated with a sulfonylurea drug, because of concern about teratogenicity and neonatal hypoglycemia. There is little information about the efficacy of these drugs in this group of women.